Document:

Amended and Restated Employment Agreement - Nancy C. Broadbent

 Exhibit 10.2 
 THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT is entered into by and between Orthovita, Inc., a Pennsylvania corporation having its
principal offices in Malvern, PA (the “Company”), and Nancy Broadbent (the “Executive”). 
 WHEREAS, the
Company and the Executive originally entered into an Employment Agreement effective as of May 26, 2009 in connection with the Executive’s employment as the Company’s Senior Vice President and Chief Financial Officer (the
“Original Agreement”); 
 WHEREAS, the Company and the Executive desire to amend the Original Agreement in order to
(i) with respect to equity awards granted to the Executive after 2009, eliminate the acceleration of vesting of such awards upon termination of the Executive’s employment without cause in the absence of a change of control;
(ii) modify provisions regarding “excess parachute payments” under Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”); (iii) eliminate automobile allowance payments; and (iv) comply
with recent regulations issued under Section 409A of the Code (the Original Agreement, as amended and restated herein, is referred to as the “Agreement”); 
 NOW, THEREFORE, in consideration of the premises and of the mutual covenants and agreements hereinafter set forth, the Company and the Executive hereby agree that the Agreement is amended and restated in
its entirety to read as follows: 
 1. Employment. 
 (a) Term. The initial term of this Agreement shall begin as of January 1, 2010 (the “Effective Date”) and shall
continue until May 25, 2011, unless sooner terminated by either party as hereinafter provided. In addition, the term of this Agreement shall automatically renew for periods of one year unless either party gives written notice to the other party
at least 180 days prior to the end of the Term or at least 180 days prior to the end of any one-year renewal period that the Agreement shall not be further extended; provided, however, that if a Change of Control (as defined below) shall occur
during the Term, the Term shall expire no earlier than 12 months beyond the month in which the Change of Control occurred. The period commencing on the Effective Date and ending on the date on which the term of the Executive’s employment under
the Agreement terminates is referred to herein as the “Term.” In no event shall the expiration of this Agreement be deemed, in and of itself, a termination of the Executive’s employment for purposes of this Agreement, including
a termination without Cause for purposes of Section 7. 
 (b) Duties. 
 (i) The Executive shall serve as the Senior Vice President and Chief Financial Officer of the Company with duties,
responsibilities and authority commensurate therewith and shall report to the Chief Executive Officer. The Executive shall perform all duties and accept all responsibilities incident to such position as may be reasonably assigned to her by the Chief
Executive Officer. 

 (ii) The Executive represents to the Company that she is not subject to or a
party to any employment agreement, non-competition covenant, understanding or restriction which would be breached by or prohibit the Executive from executing this Agreement and performing fully her duties and responsibilities hereunder. 

(c) Best Efforts. During the Term, the Executive shall devote her best efforts and full time and attention to promote the business
and affairs of the Company and its affiliated entities, and shall be engaged in other business activities only to the extent that such activities do not materially interfere or conflict with the Executive’s obligations to the Company hereunder,
including, without limitation, obligations pursuant to Section 14 below. The foregoing also shall not be construed as preventing the Executive from (1) serving on civic, educational, philanthropic or charitable boards or committees, or,
with the prior written consent of the Board of Directors of the Company (the “Board”), in its sole discretion, on corporate boards, and (2) managing personal investments, so long as such activities are permitted under the
Company’s Code of Conduct and employment policies. Notwithstanding any provision of this Section 1 of the Agreement to the contrary, in no event shall the Executive invest in any business competitive with the Company or that would
otherwise violate the provisions of Section 14 below (other than as a shareholder of less than 1% of a publicly traded company). 
 2. Base Salary and Bonus. 
 (a) During the Term, for all of the services rendered by the Executive hereunder,
the Company shall pay Executive a base salary (“Base Salary”), at the initial annual rate of $284,900, payable in installments at such times as the Company customarily pays its other employees; provided that the Base Salary shall increase
to $292,100 as of April 1, 2010 upon the concurrent elimination of automobile allowance payments in the amount of $600 per month. The Executive’s Base Salary shall be reviewed periodically by the Board (or a committee of the Board)
pursuant to the Board’s normal performance review policies for senior level executives. 
 (b) In addition, during the
Term, the Executive shall be eligible to receive an annual bonus based on the attainment of individual and corporate performance goals and targets, as determined by the Board (or a Board committee), in its sole discretion, as of the beginning of
each fiscal year. The target bonus for the Executive for any calendar year during the Term shall be as established by the Board or Board committee, provided, however that the Executive’s target bonus opportunity shall be based on not less than
50% of the Executive’s Base Salary in effect for such calendar year. Promptly after receipt of the financial or other information on which the performance goals are based after the end of the fiscal year, the Board (or Board committee) shall
review actual performance against the applicable performance goals and targets and shall notify the Executive of the amount of the Executive’s bonus, if any. The Executive’s bonus shall be paid to her after the end of the fiscal year to
which it relates, at the same time and under the same terms and conditions as other executives of the Company; provided that in no event shall the Executive’s bonus be paid later than March 15 of the calendar year following the fiscal year
for which it was earned. 
  

 2 

 3. Retirement and Welfare Benefits. The Executive shall be eligible to participate in
the Company’s health, life insurance, long and short-term disability, dental, retirement, savings and medical programs, directors and officers liability insurance and other benefit plans or programs generally made available to other senior
level executive officers of the Company, if any, pursuant to their respective terms and conditions. In addition, the Executive shall be eligible to participate in any long-term equity incentive programs (including the Company’s 2007 Omnibus
Equity Compensation Plan and any successor plan) established by the Company for its senior level executives generally at levels determined by the Board (or a Board committee) in its sole discretion, commensurate with the Executive’s position as
Senior Vice President and Chief Financial Officer. Nothing in this Agreement shall preclude the Company or any affiliate of the Company from terminating or amending any employee benefit plan or program from time to time after the Effective Date.

 4. Vacation. The Executive shall be entitled to vacation, holiday and sick leave at levels commensurate with those
provided to other senior executive officers of the Company, in accordance with the Company’s vacation, holiday and other pay for time not worked policies. 
 5. Intentionally omitted. 
 6. Expenses. The Company shall reimburse
the Executive for all necessary and reasonable travel and other business expenses incurred by the Executive in the performance of his/her duties hereunder in accordance with such reasonable accounting procedures as the Company may adopt generally
from time to time for executives. 
 7. Termination Without Cause; Resignation for Good Reason following a Change of
Control. The provisions of this Section 7 shall apply if either (i) the Executive’s employment is terminated by the Company without Cause (as defined in Section 13 below) or (ii) the Executive resigns under this
Section 7 for Good Reason within 12 months following a Change of Control. The Executive shall give the Company not less than 30 days’ prior written notice of such resignation. 
 (a) The Company may terminate the Executive’s employment with the Company at any time without Cause upon not less than 30 days’
prior written notice to the Executive; provided that, in the event that such notice is given, the Executive shall be under no obligation to render any additional services to the Company and shall be allowed to seek other employment. In addition, on
the date of the Executive’s termination of employment for any reason, the Executive agrees to resign all positions, including as an officer and, if applicable, as a director or member of the board of directors, of the Company and its parents,
subsidiaries and affiliates. 
 (b) Unless the Executive complies with the provisions of Section 7(c) below, upon
termination without Cause at any time or resignation for Good Reason following a Change of Control under Section 7(a) above, the Executive shall be entitled to receive only the amount due to the Executive under the Company’s then current
severance pay plan for employees, if any, but only to the extent not conditioned on the execution of a release by the Executive. No other payments or benefits shall be due under this Agreement to the Executive, but the Executive shall be entitled to
any benefits accrued and due in accordance with the terms of any applicable benefit plans and programs of the Company. 
  

 3 

 (c) Notwithstanding the provisions of Section 7(b), upon termination without Cause at
any time or resignation for Good Reason following a Change of Control under Section 7(a) above, as applicable, if the Executive executes and does not revoke a written release, in a form acceptable to the Company, in its sole discretion,
of any and all claims against the Company and all related parties with respect to all matters arising out of the Executive’s employment by the Company, or the termination thereof (other than claims for any entitlements under the terms of this
Agreement or under any plans or programs of the Company under which the Executive has accrued and is due a benefit) (the “Release”), the Executive shall be entitled to receive, in lieu of the payment described in Section 7(b) and any
other payments due under any severance plan or program for employees or executives, the following: 
 (i) An
amount equal to 18 months of the Executive’s annual Base Salary (at the rate in effect immediately before the Executive’s termination), payable in normal installments in accordance with the Company’s payroll practices; provided,
however, that if Executive’s termination without Cause occurs prior to a Change of Control or after 12 months following a Change of Control, the amount payable under this Section 7(c)(i) shall equal 12 months. Payments shall
commence within 60 days after the effective date on which the Executive’s employment terminates, on the first payroll date following expiration of the maximum revocation period applicable to the Release, except as provided in
Section 7(c)(vi) below. 
 (ii) A pro rata bonus for the year in which the Executive’s termination of
employment occurs to the extent that such amount would have been earned in accordance with the terms of the Company’s annual incentive program only with respect to the calendar year in which the Executive’s termination of employment
occurs, without regard to a requirement, if any, that the Executive be employed by the Company on the date of payment. The pro-rata bonus shall be payable at the date on which other bonuses are paid for the year after the end of the fiscal year to
which it relates; provided that in no event shall the Executive’s pro rata bonus be paid later than March 15 of the calendar year following the fiscal year for which it was earned, except as provided in Section 7(c)(vi) below.

 (iii) A monthly payment, on the first payroll date of each month, equal to the monthly Executive’s COBRA
health care continuation coverage premium under Section 4980B of the Code under the Company’s medical plan, for the period following the Executive’s termination equal in duration to the severance period described in
Section 7(c)(i) above or until the date on which the Executive is eligible for coverage under a plan maintained by a new employer or under a plan maintained by his/her spouse’s employer, whichever is sooner, for himself/herself and, where
applicable, his/her spouse and dependents. 
 (iv) Notwithstanding any provision to the contrary in any
applicable plan, program or agreement, all outstanding stock options, restricted stock, restricted stock units and other equity rights held by the

  

 4 

 
Executive as of the date of the Executive’s resignation for Good Reason within 12 months following a Change of Control or termination without Cause within 12 months following a Change of
Control will become fully vested and exercisable as of the date on which the Executive’s resignation for Good Reason or termination without Cause following a Change of Control occurs. In addition, all outstanding stock options, restricted
stock, restricted stock units and other equity rights granted to the Executive prior to 2010 and held by the Executive as of the date of the Executive’s termination without Cause at any time will become fully vested and exercisable as of the
date on which such termination without Cause occurs. This subsection 7(c)(iv) shall not apply upon Non-Renewal. 
 (v) Any other amounts earned, accrued and owing but not yet paid under Section 2 above (Base Salary and Bonus) and any benefits accrued and due under any applicable benefit plans and programs of the Company. 
 (vi) If the Executive is determined to be a Specified Executive (as defined in Section 13(e) below), any amounts payable
to her upon separation from service that are deferred compensation under Section 409A of the Code shall be postponed and shall be paid in a lump sum after the first to occur of (i) the date that is six months following the Executive’s
separation from service or (ii) the Executive’s death. The lump sum payment of such postponed amounts shall be made within five days following the end of the six-month period or within 60 days following the Executive’s death, as
applicable. The Section 409A postponement period shall not apply to: 
 (1) separation pay that is exempt
from Section 409A under the separation pay exception, which exempts an amount up to two times the lesser of (a) the Executive’s annualized compensation for the year prior to the year of separation, or (b) the maximum amount that
may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code and which is paid no later than the last day of the Executive’s second taxable year following the taxable year in which her separation from service
occurs; and 
 (2) any amount exempt from Section 409A under the short term deferral exception. 

8. Voluntary Termination. The Executive may voluntarily terminate his/her employment for any reason upon 30 days’ prior
written notice. In such event, after the effective date of such termination, no payments shall be due under this Agreement, except that the Executive shall be entitled to any amounts earned, accrued and owing but not yet paid under Section 2
above and any benefits accrued and due under any applicable benefit plans and programs of the Company. 
 9. Disability.
If the Executive incurs a Disability (as defined in Section 13 below) during the Term, the Executive’s employment shall terminate on the date of Disability. If the

  

 5 

 
Executive’s employment terminates on account of Disability, the Executive shall be entitled to receive any amounts earned, accrued and owing but not yet paid under Section 2 above and
any benefits accrued and due under any applicable benefit plans and programs of the Company. 
 10. Death. If the
Executive dies while employed by the Company, the Executive’s employment shall terminate on the date of death and the Company shall pay to the Executive’s executor, legal representative, administrator or designated beneficiary, as
applicable, any amounts earned, accrued and owing but not yet paid under Section 2 above and any benefits accrued and due under any applicable benefit plans and programs of the Company. Otherwise, the Company shall have no further
liability or obligation under this Agreement to the Executive’s executors, legal representatives, administrators, heirs or assigns or any other person claiming under or through the Executive. 
 11. Cause. The Company may terminate the Executive’s employment at any time for Cause upon written notice to the Executive, in
which event all payments under this Agreement shall cease, except for any amounts earned, accrued and owing but not yet paid under Section 2 above and any benefits accrued and due under any applicable benefit plans and programs of the Company.

 12. Change of Control. 
 (a) Acceleration of Equity Rights. Notwithstanding any provision to the contrary in any applicable plan, program or agreement, upon the occurrence of a Change of Control (as defined in
Section 13 below) during the Term, all outstanding stock options, restricted stock, restricted stock units and other equity rights held by the Executive as of the date of the Change of Control will become fully vested and exercisable as of the
date on which the Change of Control occurs. 
 (b) Application of Section 280G of the Code. In the event a Change of
Control occurs and the Executive becomes entitled to any benefits or payments in the nature of compensation (within the meaning of Section 280G(b)(2) of the Code) under this Agreement, or any other plan, arrangement, or agreement with the
Company (the “Payments”), and such benefits or payments would (in the absence of this Section 12(b)) be subject to the tax (the “Excise Tax”) imposed by Section 4999 of the Code (or any similar tax that may hereafter be
imposed), the aggregate present value of the Payments under this Agreement shall be reduced (but not below zero) to the Reduced Amount (as defined below), if reducing the Payments under this Agreement will provide the Executive with a greater net
after-tax amount than would be the case if no reduction was made. The “Reduced Amount” shall be an amount expressed in present value which maximizes the aggregate present value of Payments without causing any Payment under this
Agreement to be subject to the Excise Tax, determined in accordance with Section 280G(d)(4) of the Code. The Company shall reduce the Payments under this Agreement by first reducing Payments that are payable in cash and then by reducing
non-cash Payments. The fact that the Executive’s right to payments or benefits may be reduced by reason of the limitations contained in this Section 12(b), shall not of itself limit or otherwise affect any other rights of the Executive
other than pursuant to this Agreement. 
  

 6 

 (i) Determinations; Timing of Payments. All determinations to be
made under this Section 12(b) shall be made by the Company’s independent public accounting firm as in effect immediately prior to the Change of Control or another qualified independent firm selected by the Company before the Change of
Control (the “Accounting Firm”), which firm shall provide its determinations and any supporting calculations to the Company and Chief Executive Officer within 10 business days of the event that gives rise to the “excess parachute
payment.” Any such determination by the Accounting Firm shall be binding upon the Company and the Executive. Within five days after the Accounting Firm’s determination, the Company shall pay (or cause to be paid) or distribute (or cause to
be distributed) to or for the benefit of the Executive such amounts as are then due to the Executive under this Agreement. 
 (ii) Computation. For purposes of determining whether any of the Payments will be subject to the Excise Tax, the amount of such Excise Tax, and the amount of any Reduced Amount, the Accounting Firm
shall take into account any relevant guidance under the Code and the regulations thereunder, including, but not limited to, the following: 
 (A) The amount of the Payments which shall be treated as subject to the Excise Tax shall be equal to the amount of excess parachute payments within the meaning of Section 280G(b)(1) of the Code, as
determined by the Accounting Firm; 
 (B) The value of any non-cash benefits or any deferred or accumulated
payment or benefit shall be determined by the Accounting Firm in accordance with the principles of Sections 280G(d)(3) and (4) of the Code; and 
 (C) The value of the non-competition covenants contained in this Agreement shall be taken into account to reduce “parachute payments” to the maximum extent allowable under Section 280G of
the Code. The Company or the Accounting Firm may retain a third-party valuation expert in order to determine the value of such covenants. The Accounting Firm shall be entitled to rely upon such expert valuation in making its determinations under
this Section 12. 
 For purposes of the determinations under this Section 12, the Executive shall be
deemed to pay federal income taxes at the highest marginal rate of federal income taxation in the calendar year in which the applicable payment is to be made, and state and local income taxes at the highest marginal rate of taxation in the state and
locality of the Executive’s residence, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. 
  

 7 

 (iii) Overpayments and Underpayments. If as a result of a final IRS
determination that any payments will have been made by the Company which should not have been made (“Overpayment”), consistent with the calculations required to be made hereunder, any such Overpayment shall be treated for all purposes as a
loan to the Executive which the Executive shall repay to the Company, together with interest at the applicable Federal rate provided for in Section 7872(f)(2) of the Code (the “Federal Rate”). If as a result of a final IRS
determination that additional payments which have not been made by the Company could have been made (“Underpayment”), consistent with the calculations required to be made hereunder, any such Underpayment shall be promptly paid by the
Company to or for the benefit of the Executive, together with interest at the Federal Rate. 
 (iv) Fees.
All of the fees and expenses of the Accounting Firm in performing the determinations referred to this Section 12(b) shall be borne solely by the Company. 
 (v) Statutory Application. The limitations of this Section 12(b) shall only apply if payments under this
Agreement are subject to Section 280G at the time of the Change of Control. 
 13. Definitions. 
 (a) Disability. For purposes of this Agreement, the term “Disability” shall mean the Executive is unable substantially to
perform the essential duties and responsibilities under this Agreement to the full extent required by the Board by reason of mental or physical illness, injury or any other cause for six consecutive months, or for more than nine months in the
aggregate during any period of 12 consecutive calendar months. 
 (b) Cause. For purposes of this Agreement,
“Cause” shall mean any of the following grounds for termination of the Executive’s employment: (i) the Executive is convicted of a felony, (ii) in the reasonable determination of the Board, the Executive has committed an
intentional act of fraud, embezzlement, or theft or engaged in gross negligence in connection with the Executive’s duties in the course of his/her employment with the Company, (iii) the Executive intentionally breached the Executive’s
obligations under this Agreement, including inattention to or neglect of duties and shall not have remedied such breach within 30 days after receiving written notice from the Board specifying the details thereof, provided, however, that in any case
under this clause (iii), the act or failure to act by the Executive is materially harmful to the business of the Company, and (iv) the failure by the Executive to follow the lawful directives of the Company’s Chief Executive Officer or its
Board, provided that (other than in the case of those actions or omissions set forth in clause (i) and (ii) above) the Executive shall have been given reasonably detailed notice that such an event constituting Cause for termination has
occurred and shall have been given at least 30 days opportunity to take remedial action but shall have failed or refused to do so. For purposes of this Agreement, an act or omission on the part of the Executive shall be deemed
“intentional” or “gross negligence” only if it was done by the Executive in bad faith, not merely an error in judgment, and without reasonable belief that the act or omission was in the best interest of the Company. 

 

 8 

 (c) Good Reason. For purposes of this Agreement, the occurrence of one or more of the
following actions after the occurrence of a Change of Control shall constitute “Good Reason”: (i) a material diminution in the Executive’s duties, responsibilities or authority, (ii) a material reduction in the
Executive’s Base Salary except as part of an across the board reduction applicable to executives generally, or (iii) a failure of the Company to comply with any of the material terms of this Agreement, provided that the Company shall have
been given reasonably detailed written notice that such an event constituting cause for termination has occurred and shall have been given at least 30 days opportunity to take remedial action but shall have failed or refused to do so. The Executive
must give the Company written notice within 90 days following the event that constitutes Good Reason and the Executive’s termination must occur within one year following such event. 
 (d) Change of Control. For purposes of this Agreement, “Change of Control” shall have the same meaning ascribed to such
term under the Company’s 2007 Omnibus Equity Compensation Plan, as in effect on the date hereof and as it may be amended from time to time, or any successor plan. 
 (e) Specified Executive. For purposes of this Agreement, “Specified Executive” shall mean an employee who, at any time during the 12-month period ending on the identification date
(defined below), is (i) an officer of the Company or a member of its controlled group (as determined for purposes of Section 416(i) of the Code) who has annual compensation greater than $135,000 (or such other amount as may be in effect
under Section 416(i)(1) of the Code), (ii) a 5% owner of the Company or (iii) a 1% owner of the Company who has annual compensation greater than $150,000. The identification date shall be each December 31, and the determination
of Specified Executives as of such identification date shall apply for the 12-month period following April 1 after the identification date. The determination of Specified Executives, including the number and identity of persons considered
officers, shall be made by the Company in accordance with the provisions of Sections 416(i) and 409A of the Code and the regulations issued thereunder. 
 14. Restrictive Covenants. 
 (a) Non-Competition. During the Term,
and for the 12-month period beginning on the date the Executive’s employment terminates, for any reason (the “Restriction Period”), the Executive hereby agrees that he/she will not, without the Company’s express written consent,
engage (directly or indirectly) in any employment or business activity which designs, manufactures, sells, licenses or markets any technologies or competing products of the Company or any of its subsidiaries or affiliates, or would otherwise
conflict with the Executive’s employment by the Company. Such products and technologies include those products and technologies which the Company or any of its subsidiaries or affiliates has developed, manufactured, sold, licensed or marketed
now or, at the time of termination of Executive’s employment, may be in the process of developing, manufacturing, selling, licensing or marketing. 
 (b) Non-Solicitation and Non-Hire of Company Personnel. During the Term and for the Restriction Period, the Executive hereby agrees that he/she will not, either directly or through others, hire or
attempt to hire, any current or former employee of the Company, or solicit or

  

 9 

 
attempt to solicit any current or former employee, consultant or independent contractor of the Company to change or terminate his, her or its relationship with the Company or otherwise to become
an employee for or of any other person or business entity, unless more than 12 months shall have elapsed between the last day of such person’s employment or service with the Company and the first date of such solicitation or hiring or attempt
to solicit or hire. 
 (c) Non-Solicitation of Customers. During the Term and for the Restriction Period, the Executive
hereby agrees that he/she will not, either directly, through others or on behalf of third parties, solicit, divert or appropriate, or attempt to solicit, divert or appropriate any customer or actively sought prospective customer of the Company for
the purpose of providing such customer or actively sought prospective customer with services or products competitive with those offered by the Company during the Term. 
 (d) Non-Disparagement. Executive agrees that Executive will not disparage the Company, its subsidiaries and parents, and their respective officers, directors, employees, and agents, and its and
their respective successors and assigns, heirs, executors, and administrators, or make any public statement reflecting negatively on the Company, its subsidiaries and parents, and their respective officers, directors, employees, and agents, and its
and their respective successors and assigns, heirs, executors, and administrators, to third parties, including any matters relating to the operation or management of the Company, irrespective of the truthfulness or falsity of such statement.

 (e) Proprietary Information. At all times during the Term and at all times thereafter, the Executive will hold
in strictest confidence and will not disclose, use, lecture upon or publish any of the Company’s Proprietary Information (as defined below), except as such disclosure, use or publication may be required in connection with the Executive’s
work for the Company, or unless the Company expressly authorizes such disclosure in writing or disclosure is required by law or in a judicial or administrative proceeding, in which event the Executive shall promptly notify the Company of the
required disclosure and assist the Company if it determines to resist the disclosure. “Proprietary Information” shall mean any and all confidential and/or proprietary knowledge, data or information of the Company, its affiliated entities
and partners, including but not limited to information relating to financial matters, investments, budgets, business plans, marketing plans, personnel matters, business contacts, products, processes, know-how, designs, methods, improvements,
discoveries, inventions, ideas, data, programs, and other works of authorship. 
 (f) Invention Assignment. The Executive
agrees that all inventions, innovations, improvements, developments, methods, designs, analyses, reports, and all similar or related information which relates to the Company’s actual or anticipated business, research and development or existing
or future products or services and which are conceived, developed or made by Executive while employed by the Company (“Work Product”) belong to the Company. The Executive will promptly disclose such Work Product to the Board and perform
all actions reasonably requested by the Board (whether during or after the Term) to establish and confirm such ownership (including, without limitation, assignments, consents, powers of attorneys and other instruments). 
  

 10 

 (g) Return of Company Property. Upon termination of the Executive’s
employment with the Company for any reason whatsoever, voluntarily or involuntarily, and at any earlier time the Company requests, the Executive will deliver to the person designated by the Company all originals and copies of all documents and
property of the Company in the Executive’s possession, under the Executive’s control or to which the Executive may have access. The Executive will not reproduce or appropriate for the Executive’s own use, or for the use of others, any
property, Proprietary Information or Company inventions. 
 15. Legal and Equitable Remedies. Because the
Executive’s services are personal and unique and the Executive has had and will continue to have access to and has become and will continue to become acquainted with the proprietary information of the Company, and because any breach by the
Executive of any of the restrictive covenants contained in Section 14 would result in irreparable injury and damage for which money damages would not provide an adequate remedy, the Company shall have the right to enforce Section 14 and
any of its provisions by injunction, specific performance or other equitable relief, without bond and without prejudice to any other rights and remedies that the Company may have for a breach, or threatened breach, of the restrictive covenants set
forth in Section 14. The Executive agrees that in any action in which the Company seeks injunction, specific performance or other equitable relief, the Executive will not assert or contend that any of the provisions of Section 14 are
unreasonable or otherwise unenforceable. The Executive irrevocably and unconditionally (a) agrees that any legal proceeding arising out of this paragraph may be brought in the United States District Court for the Eastern District of
Pennsylvania, or if such court does not have jurisdiction or will not accept jurisdiction, in any court of general jurisdiction in Chester County, Pennsylvania, (b) consents to the non-exclusive jurisdiction of such court in any such
proceeding, and (c) waives any objection to the laying of venue of any such proceeding in any such court. The Executive also irrevocably and unconditionally consents to the service of any process, pleadings, notices or other papers. 

16. Arbitration; Expenses. In the event of any dispute under the provisions of this Agreement, other than a dispute in which the
primary relief sought is an equitable remedy such as an injunction, the parties shall be required to have the dispute, controversy or claim settled by arbitration in Philadelphia, Pennsylvania in accordance with the National Rules for the Resolution
of Employment Disputes then in effect of the American Arbitration Association, before an arbitrator agreed to by both parties. If the parties cannot agree upon the choice of arbitrator, the Company and Executive will each choose an arbitrator. The
two arbitrators will then select a third arbitrator who will serve as the actual arbitrator for the dispute, controversy or claim. Any award entered by the arbitrators shall be final, binding and nonappealable and judgment may be entered thereon by
either party in accordance with applicable law in any court of competent jurisdiction. This arbitration provision shall be specifically enforceable. The arbitrators shall have no authority to modify any provision of this Agreement or to award a
remedy for a dispute involving this Agreement other than a benefit specifically provided under or by virtue of the Agreement. Each party shall be responsible for its own expenses, unless the Executive shall prevail in an arbitration proceeding as to
any material issue, in which case the Company shall reimburse the Executive for all reasonable costs, expenses and fees relating to the conduct of the arbitration (including reasonable attorneys’ fees and expenses) and shall share the fees of
the American Arbitration Association. 
  

 11 

 17. Survival. The respective rights and obligations of the parties hereunder shall
survive the termination of this Agreement to the extent necessary to the intended preservation of such rights and obligations. 
 18. Mitigation. The Company’s obligations to make payments under this Agreement and otherwise to perform its obligations hereunder shall not be affected by any circumstances, including, without limitation, any set-off,
counterclaim, recoupment, defense or other right which the Company may have against Executive or others. 
 19. Notices.
All notices and other communications required or permitted under this Agreement or necessary or convenient in connection herewith shall be in writing and shall be deemed to have been given when hand delivered or mailed by registered or certified
mail, as follows (provided that notice of change of address shall be deemed given only when received): 
 If to the Company, to:

 Orthovita, Inc. 
 77 Great Valley Parkway 
 Malvern, PA 19355 
 Attention: Vice President, Human Resources 
 If to the Executive, to the most recent address on file with the Company or to such other names or addresses as the Company or the Executive, as the case may be, shall designate by notice to each other
person entitled to receive notices in the manner specified in this Section or as provided on the Company’s website, www.orthovita.com. 
 20. Withholding. All payments under this Agreement shall be made subject to applicable tax withholding, and the Company shall withhold from any payments under this Agreement all federal, state and
local taxes that the Company is required to withhold pursuant to any law or governmental rule or regulation. The Executive shall bear all expense of, and be solely responsible for, all federal, state and local taxes due with respect to any payment
received under this Agreement. 
 21. Remedies Cumulative; No Waiver. No remedy conferred upon a party by this Agreement
is intended to be exclusive of any other remedy, and each and every such remedy shall be cumulative and shall be in addition to any other remedy given under this Agreement or now or hereafter existing at law or in equity. No delay or omission by a
party in exercising any right, remedy or power under this Agreement or existing at law or in equity shall be construed as a waiver thereof, and any such right, remedy or power may be exercised by such party from time to time and as often as may be
deemed expedient or necessary by such party in its sole discretion. 
 22. Assignment. All of the terms and provisions of
this Agreement shall be binding upon and inure to the benefit of and be enforceable by the respective heirs, executors, administrators, legal representatives, successors and assigns of the parties hereto, except that the duties and responsibilities
of the Executive under this Agreement are of a personal nature and shall not be assignable or delegable in whole or in part by the Executive. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation,

  

 12 

 
reorganization or otherwise) to all or substantially all of the business or assets of the Company, within 15 days of such succession, expressly to assume and agree to perform this Agreement in
the same manner and to the same extent as the Company would be required to perform if no such succession had taken place and the Executive acknowledges that in such event the obligations of the Executive hereunder, including but not limited to those
under Sections 14 and 15, will continue to apply in favor of the successor. 
 23. Entire Agreement. This Agreement sets
forth the entire agreement of the parties hereto and supersedes any and all prior agreements and understandings concerning the Executive’s employment by the Company. This Agreement may be changed only by a written document signed by the
Executive and the Company. 
 24. Section 409A of the Code. 
 (a) This Agreement is intended to comply with Section 409A of the Code and its corresponding regulations, or an exemption, and payments
may only be made under this Agreement upon an event and in a manner permitted by Section 409A, to the extent applicable. Severance benefits under the Agreement are intended to be exempt from Section 409A under the “separation pay
exception,” to the maximum extent applicable, or another exemption. Notwithstanding anything in this Agreement to the contrary, if required by Section 409A, if the Executive is considered a “specified employee” for purposes of
Section 409A and if payment of any amounts under this Agreement is required to be delayed for a period of six months after separation from service pursuant to Section 409A, payment of such amounts shall be delayed as required by
Section 409A, and the accumulated amounts shall be paid in a lump sum payment within ten days after the end of the six-month period. If the Executive dies during the postponement period prior to the payment of benefits, the amounts withheld on
account of Section 409A shall be paid to the personal representative of the Executive’s estate within 60 days after the date of the Executive’s death. 
 (b) All payments to be made upon a termination of employment under this Agreement may only be made upon a “separation from service” under Section 409A. For purposes of Section 409A of
the Code, the right to a series of payments under this Agreement shall be treated as a right to a series of separate payments. In no event may the Executive, directly or indirectly, designate the calendar year of a payment. All reimbursements and
in-kind benefits provided under the Agreement shall be made or provided in accordance with the requirements of Section 409A. 
 25. Severability. If any provision of this Agreement or application thereof to anyone or under any circumstances is adjudicated to be invalid or unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect
any other provision or application of this Agreement which can be given effect without the invalid or unenforceable provision or application and shall not invalidate or render unenforceable such provision or application in any other jurisdiction. If
any provision is held void, invalid or unenforceable with respect to particular circumstances, it shall nevertheless remain in full force and effect in all other circumstances. 
  

 13 

 26. Governing Law. This Agreement shall be governed by, and construed and enforced in
accordance with, the substantive and procedural laws of the Commonwealth of Pennsylvania without regard to rules governing conflicts of law. 
 27. Counterparts. This Agreement may be executed in any number of counterparts (including facsimile counterparts), each of which shall be an original, but all of which together shall constitute one
instrument. 
 [SIGNATURE PAGE FOLLOWS] 
  

 14 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement on March 9, 2010.

  

			
	ORTHOVITA, INC.
		
	By:	 	 /s/ Antony Koblish

		 	President and Chief Executive Officer
	
	EXECUTIVE
	
	 /s/ Nancy C. Broadbent

  

 15Executive Employment Agreement

 EXHIBIT 10.29 
  
  
 BETWEEN: 
 JEFFREY M. GROSS 
 AND: 
 ANGIOTECH PHARMACEUTICALS,
INC. 
  
  
 EXECUTIVE EMPLOYMENT AGREEMENT 
  
  
 Davis LLP 
 2800 Park Place 
 666
Burrard Street 
 Vancouver, BC V6C 2Z7 
  

			
	 66216-00015
	  	AAS/mef

  
  

 EXECUTIVE EMPLOYMENT AGREEMENT 
 This Agreement dated October 29, 2008 
 BETWEEN: 
 JEFFREY M. GROSS, of 3275 West 22nd Street, 
 Vancouver, BC, V6L 1N1 
 (“Executive”) 
 AND: 
 ANGIOTECH PHARMACEUTICALS, INC., 
 a corporation incorporated under the laws of British Columbia 
 (“Angiotech”) 
 BACKGROUND 
 A. Angiotech wishes to continue to employ the Executive in the position of Senior Vice President, Research & Development, on and subject to the
terms and conditions of this Agreement. 
 B. The Executive wishes to continue to be so employed. 
 AGREEMENTS 
 For good and
valuable consideration, the receipt and sufficiency of which each party acknowledges, the parties agree as follows: 
  

	1.	EMPLOYMENT 

 1.1 Angiotech will employ the
Executive, and the Executive will serve Angiotech, subject to and in accordance with the terms of this Agreement. 
 1.2 The Executive:

  

	 	(a)	will be employed in the position of Senior Vice President, Research & Development at Angiotech’s offices in Vancouver, British Columbia;

  

	 	(b)	will report to Angiotech’s Chief Executive Officer; and 

  

	 	(c)	will perform those duties and responsibilities assigned to the Executive by Angiotech from time to time. 

 1.3 Angiotech may ask the Executive to serve as an officer of Angiotech, and/or as a director and/or officer
of one or more of Angiotech’s affiliates or subsidiaries. 
 1.4 The Executive will be employed by Angiotech on a full-time basis, and
agrees that: 
  

	 	(a)	the Executive’s hours of work will vary, and will be those hours required to perform the Executive’s duties and responsibilities under this Agreement; and

  

	 	(b)	the remuneration paid to the Executive under this Agreement constitutes remuneration, compensation, and payment in full for all hours worked and all services provided
by the Executive in connection with the Executive’s employment with Angiotech or otherwise, including any work performed or services provided as a director or officer of Angiotech or any of its affiliates or subsidiaries.

 1.5 Angiotech may, from time to time, establish or change written policies and procedures concerning its business and the
conduct of its employees, which will, upon publication to the Executive, be binding on the Executive as if incorporated into this Agreement, provided that if there is a conflict between the terms of such policies and procedures and the terms of this
Agreement, the terms of this Agreement will prevail and govern. 
 1.6 This Agreement is effective as of October 20, 2008 (“Effective
Date”), and will continue in effect until terminated by either party in accordance with its terms. 
 1.7 The first day of the
Executive’s employment continues to be July 3, 2007 for all purposes under this Agreement, which will also continue to be the anniversary date of the Executive’s employment for all purposes under this Agreement. 
  

	2.	EXCLUSIVE SERVICE 

 2.1 The Executive
will, to the best of the Executive’s ability, diligently and faithfully devote all of the Executive’s business time, attention, energies, and abilities exclusively to the Business of Angiotech and the performance of the Executive’s
duties and responsibilities under this Agreement, and will at all times use best efforts to promote the interests of Angiotech. 
 2.2 During
the Executive’s employment with Angiotech, the Executive will not, directly or indirectly: 
  

	 	(a)	be employed by or render services of a business, professional, or commercial nature, including services as an owner, shareholder, partner, joint venturer, officer,
director, employee, advisor, contractor, consultant, agent, or otherwise, to any other person, firm, entity, or business, whether for remuneration or otherwise, without the prior written authorization of Angiotech’s Chief Executive Officer; or

  

	 	(b)	otherwise engage in any activity that is competitive with the Business of Angiotech, or that negatively affects the performance of the Executive’s duties and
responsibilities under this Agreement, whether alone, or as an owner, shareholder, partner, joint venturer, officer, director, employee, advisor, contractor, consultant, or agent of any other person, firm, entity, or business.

  

 - 2 - 

 2.3 For greater certainty, paragraph 2.2(b) does not, subject to Part 11, restrict the Executive from:

  

	 	(a)	with Angiotech’s prior written authorization under paragraph 2.2(a), rendering services to, or serving as an officer or director of, a person, firm, entity, or
business that is not a Competitor of Angiotech; 

  

	 	(b)	investing in a firm, entity, or business that is not a Competitor of Angiotech; 

  

	 	(c)	owning a legal or beneficial interest not exceeding 1% in a Competitor of Angiotech; or 

  

	 	(d)	engaging in charitable activities with a social or philanthropic purpose that do not have a material negative effect on the performance of the Executive’s duties
and responsibilities under this Agreement or on the interests of Angiotech. 

  

	3.	FIDUCIARY DUTY 

 3.1 The Executive has a
fiduciary relationship with Angiotech, whereby the Executive has an absolute duty of trust, care, fidelity, and honesty to Angiotech, including a duty to avoid any conflict of interest, and to act with undivided loyalty to Angiotech and with the
utmost good faith, exclusively and selflessly in the best interests of Angiotech. 
  

	4.	BASE SALARY 

 4.1 Angiotech will pay the
Executive an annual base salary of $276,925.00 per year or such other amount as the Board may determine, from time to time, in accordance with this Agreement (“Base Salary”), payable on Angiotech’s normal payroll schedule. 

4.2 The Board may, from time to time, in its sole discretion, review the Base Salary and determine if any increase is appropriate having regard to the
Executive’s performance and contributions, as assessed by the Board in its sole discretion, and any other factor or factors the Board may consider appropriate. 
  

	5.	BONUS PLAN 

 5.1 Subject to paragraph 5.3,
the Executive will be eligible to participate in Angiotech’s bonus plan for executive employees (“Bonus Plan”), which currently provides for bonuses based on a target bonus opportunity of 40% of the Base Salary earned by the Executive
during a fiscal year, provided that the Board may determine, in its sole discretion, that the amount of the payment made to the Executive under the Bonus Plan in respect of a fiscal year may be greater or lesser than the target bonus opportunity, or
that no payment will be made to the Executive from the Bonus Plan in respect of a fiscal year, having regard to individual and company performance and any other factor or factors the Board may consider appropriate. 
  

 - 3 - 

 5.2 Any one payment to the Executive under the Bonus Plan will not obligate Angiotech to make any other
payment to the Executive under the Bonus Plan or otherwise. 
 5.3 The Board may, from time to time, in its sole discretion and without prior
notice to the Executive, change or terminate the Bonus Plan. If there is a conflict between the Bonus Plan and the terms of this Agreement (other than paragraph 5.1), the terms of this Agreement (other than paragraph 5.1) will prevail and govern.

  

	6.	STATUTORY DEDUCTIONS 

 6.1 The Base
Salary, any payments under the Bonus Plan or under Part 10 or 14, and any other payment, award, or benefit made or provided to the Executive under this Agreement or otherwise are subject to all required statutory deductions and withholdings, and any
other amount required by law to be deducted or withheld from such payment. 
  

	7.	INSURANCE, RETIREMENT, AND OTHER EMPLOYEE BENEFITS 

 7.1 Subject to paragraphs 7.3 and 7.4, during the Executive’s employment with Angiotech, the Executive will be eligible to participate in: 
  

	 	(a)	the group health, dental, life insurance, and short and long term disability plans made generally available by Angiotech for its comparably situated executive
employees, and any other employee benefit plans that Angiotech may make generally available from time to time for its comparably situated executive employees, and, in each such instance, subject to and in accordance with the terms of the applicable
plan; and 

  

	 	(b)	the group RRSP plan made available by Angiotech for its comparably situated executive employees, or in any other retirement plan that Angiotech may make generally
available from time to time for its comparably situated executive employees, and, in each such instance, subject to and in accordance with the terms of the applicable plan. 

 7.2 If the Executive is a director or officer of Angiotech or any of its affiliates or subsidiaries, Angiotech will maintain a policy of directors’ and officers’ liability insurance for the
Executive while the Executive is so serving. 
 7.3 The Executive’s eligibility for any benefits under any employee benefit plan, including
any health, dental, life insurance, or disability plan, or under any retirement plan, including any group RRSP plan or other retirement plan, or under any liability insurance policy, will be determined solely on the basis of the applicable plan or
plans or insurance policy or policies, and Angiotech’s sole obligation in relation to such benefits will be: 
  

	 	(a)	to pay premium costs, or a portion or percentage thereof, on behalf of or for the benefit of the Executive, to the extent that Angiotech may generally make such
payments on behalf of or for the benefit of its comparably situated executive employees; and 

  

 - 4 - 

	 	(b)	to make contributions to the group RRSP plan or other retirement plan, for the benefit of the Executive, to the extent that Angiotech may generally make such
contributions for the benefit of its comparably situated executive employees. 

 7.4 Angiotech may, in its sole discretion and
without prior notice to the Executive, change or terminate any employee benefit or insurance coverage made available to its executive employees, including the portion or percentage of premium costs (if any) paid by Angiotech under
paragraph 7.3(a). 
 7.5 Any disputes concerning the Executive’s rights under any employee benefit plan, retirement plan, or insurance
policy must be directed against the provider of the benefit and not against Angiotech. 
 7.6 The Executive’s eligibility for any health,
dental, life insurance, disability, or other insurance or employee benefits, or to participate in any retirement plan, under this Part 7 will cease on the Last Day of Employment (subject to any applicable conversion privileges), and Angiotech will
not be liable for any sickness, injury, illness, disability, or death, or for any claims, damages, losses, costs, or expenses directly or indirectly suffered or incurred thereafter, or as a result thereof. 
  

	8.	STOCK OPTIONS AND OTHER EQUITY-BASED INCENTIVE PLANS 

 8.1 Subject to paragraph 8.2, the Executive: 
  

	 	(a)	will continue to hold any options to purchase common shares of Angiotech held by the Executive as of the Effective Date, subject to the terms of any applicable stock
option agreement, plan, or program; and 

  

	 	(b)	may, from time to time, be eligible to receive additional stock option grants, or grants or awards under other equity-based incentive plans or programs, if and to the
extent awarded to the Executive under the terms of any applicable stock option agreement, plan, or program, or other equity-based incentive plan or program, which may be approved by the Board and the shareholders of Angiotech.

 8.2 The Board may, in its sole discretion and without prior notice to the Executive, change or terminate any stock option plan
or program or any equity-based incentive plan or program referred to in paragraph 8.1, subject to the terms of the applicable plan or program that govern such change or termination, and any applicable laws or regulatory requirements; provided
that such change or termination will not, without the Executive’s written consent, adversely affect any then outstanding stock options or other grants or awards held by the Executive (unless such change or termination occurs solely as a result
of a change in applicable laws or regulatory requirements). 
 8.3 Subject to paragraph 14.8(f), if the Executive’s employment is
terminated, any rights and obligations of the Executive in respect of any then outstanding stock options or other grants or awards held by the Executive will continue to be governed by the provisions of the applicable agreement, plan, or program
referred to in paragraph 8.1. 
  

 - 5 - 

 8.4 If there is a conflict between the terms of this Agreement and the terms of any stock option agreement,
plan, or program, or other equity-based incentive plan or program, referred to in paragraph 8.1, this Agreement will prevail and govern, unless applicable laws or regulatory requirements do not permit this, in which case the terms of such stock
option agreement, plan, or program, or other equity-based incentive plan or program will prevail and govern to the extent required by such laws or regulatory requirements. 
  

	9.	VACATION 

 9.1 The Executive will receive
an annual vacation of 21 working days for each fiscal year of employment under this Agreement, prorated for partial years of employment, in accordance with Angiotech’s policies regarding vacations in effect from time to time. 
 9.2 The Executive may take an annual vacation at such times as are mutually convenient to the Executive and Angiotech, but subject to Angiotech’s
operational requirements. 
 9.3 Unless otherwise provided in Angiotech’s policies regarding vacations, 
  

	 	(a)	if the Executive does not use all of the Executive’s vacation entitlement in a given fiscal year, the vacation not taken will be available to be used in a later
fiscal year; and 

  

	 	(b)	if the Executive’s employment is terminated before the end of a given fiscal year, the Executive will be paid for: 

  

	 	(i)	any unused vacation days for previous fiscal years; and 

  

	 	(ii)	any unused vacation days for the fiscal year in which the Executive’s employment is terminated, on a prorated basis. 

 9.4 Angiotech may, in its sole discretion and without prior notice to the Executive, change Angiotech’s policies, plans, or practices regarding
vacations. 
  

	10.	EXPENSES 

 10.1 Angiotech will, upon the
submission by the Executive of appropriate receipts, reimburse the Executive for: 
  

	 	(a)	business expenses incurred by the Executive that Angiotech, in its sole discretion, determines are reasonably necessary for the proper discharge of the Executive’s
duties and responsibilities, in accordance with Angiotech’s policies in effect from time to time; and 

  

 - 6 - 

	 	(b)	the following perquisites, for so long as Angiotech may make such perquisites generally available for its comparably situated executive employees, and up to a combined
maximum amount of $15,000 for each fiscal year: 

  

	 	(i)	automobile lease; 

  

	 	(ii)	financial or tax planning services; and 

  

	 	(iii)	health club membership. 

 10.2 On July 3,
2009, provided the Executive is still actively employed, Angiotech will provide mortgage assistance to the Executive in the form of a lump sum payment of $50,000. 
  

	11.	RESTRICTIONS ON SOLICITATION AND COMPETITION 

 11.1 In this Agreement: 
  

	 	(a)	“Business of Angiotech” means the business of Angiotech through the Executive’s Last Day of Employment, including, without limitation, the
business of researching, developing, manufacturing, and selling medical devices and/or medical implants, including, for example, stents, stent grafts, vascular grafts, vascular wraps, catheters, needles, blades, sutures (including barbed or
self-retaining sutures), filters, vascular snares, biopsy devices, guidewires, ophthalmic implants, orthopedic devices and implants, hemostats and hemostatic pads, and tissue sealants, fillers, and glues, as well as drug-loaded and/or polymer-coated
versions of these products; 

  

	 	(b)	“Competitor of Angiotech” means any person, persons, entity, firm, association, corporation, or other enterprise engaged in any business or activity,
anywhere in the world, that is or is being prepared to be in competition with the Business of Angiotech, including, without limitation, the development, manufacture, or sale of any product or service in competition with a product or service
developed, in development, manufactured, or sold by Angiotech through the Executive’s Last Day of Employment; 

  

	 	(c)	“Customer of Angiotech” means any customer or client or prospective customer or client of Angiotech to whom the Executive provided services, or for
whom the Executive transacted business, or whose identity became known to the Executive in connection with or as a consequence of the Executive’s relationship with or employment by Angiotech; 

  

	 	(d)	“Solicitation” means any direct or indirect communication of any kind, regardless of who initiates the communication, that in any way invites, advises,
encourages, or asks any person to take or refrain from taking any action. 

  

 - 7 - 

 11.2 Angiotech is engaged in the Business of Angiotech, the Business of Angiotech is worldwide in scope, and
the current and potential Competitors of Angiotech and Customers of Angiotech are located throughout the world. 
 11.3 While the Executive is
employed by Angiotech, and for a period of 12 months after the Last Day of Employment, the Executive will not, whether as an owner, shareholder, partner, joint venturer, officer, director, employee, advisor, contractor, consultant, agent, or
otherwise, either on his own or in conjunction with any person, persons, entity, firm, association, corporation, or other business enterprise, or in any other manner whatsoever, directly or indirectly: 
  

	 	(a)	carry on or engage in the Solicitation of any Customer of Angiotech, except, while the Executive is employed by Angiotech, for a purpose consistent with the performance
of the Executive’s duties and responsibilities under this Agreement; 

  

	 	(b)	interfere with, impair, or damage any relationship between Angiotech and any Customer of Angiotech; 

  

	 	(c)	carry on or engage in the Solicitation of any employee or consultant of Angiotech (including any person who was an employee or consultant of Angiotech within a period
of six months before the date of the Solicitation) to end his or her employment or consulting relationship with Angiotech, or to commence an employment or consulting relationship or any other relationship with any Competitor of Angiotech;

  

	 	(d)	carry on or engage in any business or activity that is, will be, or is being prepared to be in competition with the Business of Angiotech, and that is substantially
related to any business, activity, or services: 

  

	 	(i)	that the Executive engaged in or performed, directly or indirectly, for or on behalf of Angiotech through the Executive’s Last Day of Employment; or

  

	 	(ii)	for which the Executive had direct or indirect responsibility or oversight with Angiotech through the Executive’s Last Day of Employment; 

 

	 	(e)	advise, assist, lend money to, guarantee the debts or obligations of, or manage or supervise personnel of, any Competitor of Angiotech engaged in any business or
activity described in subparagraph (d)(i) or (ii); or 

  

	 	(f)	subject to paragraphs 11.4 and 11.5, own more than a 1% legal or beneficial interest in any Competitor of Angiotech. 

  

 - 8 - 

 11.4 If the Executive owns or acquires more than a 1% legal or beneficial interest in any entity, firm,
association, corporation, or other enterprise which is not a Competitor of Angiotech but which later becomes a Competitor of Angiotech while the Executive is employed by Angiotech, or, subject to paragraph 11.5, during the 12-month period after the
Last Day of Employment: 
  

	 	(a)	the Executive will, within 90 days after the Executive knows, or should have known, that such entity, firm, association, corporation, or other enterprise has become a
Competitor of Angiotech (or, if requested by the Executive, such longer time period as Angiotech may agree, such agreement not to be unreasonably withheld), either 

  

	 	(i)	dispose of that interest to the extent necessary to comply with paragraph 11.3(f), or 

  

	 	(ii)	notify Angiotech that the Executive owns more than a 1% legal or beneficial interest in such entity, firm, association, corporation, or other enterprise, and ask that
the Board decide whether the Executive must comply with paragraph 11.3(f); 

  

	 	(b)	if the Executive asks the Board under subparagraph (a)(ii) to decide whether the Executive must comply with paragraph 11.3(f), the Board will decide, in its sole
discretion, whether the Executive will be required to dispose of the Executive’s legal or beneficial interest in the entity, firm, association, corporation, or other enterprise that has become a Competitor of Angiotech, to the extent necessary
to comply with paragraph 11.3(f), or to any lesser extent specified by the Board, and Angiotech will notify the Executive of the Board’s decision; and 

  

	 	(c)	if the Board decides under subparagraph (b) that the Executive must dispose of any portion of the Executive’s legal or beneficial interest in the entity,
firm, association, corporation, or other enterprise that has become a Competitor of Angiotech, 

  

	 	(i)	the Executive will, within 90 days of being notified of the Board’s decision (or, if requested by the Executive, such longer time period as Angiotech may agree,
such agreement not to be unreasonably withheld), dispose of that interest to the extent required by the Board under subparagraph (b), and 

  

	 	(ii)	if the Executive incurs a loss as a result of having to comply with the Board’s decision under subparagraph (b), Angiotech will provide reasonable compensation to
the Executive for that loss, which will not, in any event, exceed the difference, if any, between the acquisition cost of the interest and the proceeds of disposition of the interest (without regard for the tax consequences of the disposition).

 11.5 Despite paragraphs 11.3 and 11.4, during the 12-month period after the Last Day of Employment, the Executive may own or
acquire more than 1% of the shares of any class of a Competitor of Angiotech that are publicly traded on a stock exchange or trade reporting system, provided that the Executive: 
  

	 	(a)	does not, on his own behalf, or in association with or on behalf of any other person, entity, or group of persons or entities acting jointly or in concert, become a
“control person” as defined under the Ontario Securities Act; and 

  

 - 9 - 

	 	(b)	otherwise complies with paragraph 11.3(a) to (e). 

 11.6 If paragraph 11.3, or any portion thereof, is found to be unreasonable or unenforceable to any extent by an arbitrator under Part 21 or by a Court of competent jurisdiction determining its validity or enforceability, whether as to the
subject matter or scope of the restriction or restrictions, the geographic area of the restriction or restrictions, or the duration of the restriction or restrictions, then the restriction or restrictions will be changed or reduced to that which is
determined to be reasonable or enforceable by the arbitrator or the Court. 
  

	12.	WORK PRODUCT 

 12.1 In this Agreement:

  

	 	(a)	“Intellectual Property” means all proprietary rights and interests in, to, or associated with Work Product, including, without limitation, all
registered and unregistered copyrights, patents, industrial designs, trade-marks, trade names, trade secrets, goodwill, all applications and all rights to file applications for all of the foregoing, and all rights of action for infringement,
misappropriation, or other misuse, and any other rights in and to the Work Product; 

  

	 	(b)	“Non-Angiotech Invention” means any concept, method, process, technology, invention, development, or other work which: 

  

	 	(i)	subject to paragraph 12.8, is disclosed in Appendix B; or 

  

	 	(ii)	is determined by the Board to be a Non-Angiotech Invention under paragraph 12.7; 

  

	 	(c)	“Work Product” means all work product of every kind, including, without limitation, all inventions, discoveries, concepts, ideas, know-how, plans,
strategies, developments, technologies, computer programs, software source and object codes, writings, formulas, algorithms, compilations, information, data, devices, designs, prototypes, drawings, diagrams, schematics, practices, processes,
methods, products, procedures, manuals, techniques, and other works of authorship, and all modifications and improvements to any of the foregoing, whether or not patented, registered, or otherwise protected, that is invented, made, created,
authored, generated, compiled, conceived, developed, completed, reduced to practice, or worked on by the Executive, whether alone or with others, whether during or outside the Executive’s working hours, and whether before or during the
Executive’s employment with Angiotech: 

  

	 	(i)	relating to the Business of Angiotech; 

  

 - 10 - 

	 	(ii)	resulting from work performed by the Executive with the use of Angiotech’s equipment, facilities, Confidential Information, materials, or personnel;

  

	 	(iii)	resulting from any work performed by the Executive for Angiotech; 

  

	 	(iv)	resulting from, based on, or using any of Angiotech’s assets, property, products, or research; or 

  

	 	(v)	relating to an opportunity that is identified by or presented to the Executive, or of which the Executive becomes aware, in whole or in part as a consequence of the
Executive’s employment with Angiotech, or the functions performed by the Executive on behalf of Angiotech; 

 but excluding any Non-Angiotech Inventions. 
 12.2 Angiotech is and will be the sole owner of all Work Product and Intellectual
Property. 
 12.3 For greater certainty: 
  

	 	(a)	the Executive irrevocably assigns and transfers to Angiotech all rights, title, and interest in and to all Work Product and Intellectual Property, and all rights of
action for infringement or other misuse, including all rights to file applications, and all pending applications, to patent, register, or record the Work Product and Intellectual Property; 

  

	 	(b)	to the extent the Executive holds or acquires legal title to any Work Product or Intellectual Property, the Executive holds it as trustee and agent for Angiotech; and

  

	 	(c)	on request by Angiotech, the Executive will, during and after the Executive’s employment with Angiotech, execute and deliver immediately to Angiotech all
instruments that Angiotech considers necessary or helpful to effect, perfect, register, or record its interest in Work Product and Intellectual Property, or to patent, register, or record Work Product and Intellectual Property in Angiotech’s
name, or to obtain, maintain, or enforce its rights and interest in Work Product and Intellectual Property in connection with any interference, litigation, opposition, or other proceeding to which Work Product or Intellectual Property is relevant,
provided that Angiotech reimburses the Executive for all reasonable expenses incurred to fulfill these obligations. 

 12.4 The
Executive irrevocably nominates, appoints, and constitutes Angiotech as the Executive’s true and lawful attorney with power to do all things and execute all documents on the Executive’s behalf as may be required to give effect to this
Part 12, including, without limitation, the actions contemplated in paragraph 12.3. The attorney so appointed may exercise this power as the attorney deems appropriate to give effect to the intent of this Part 12. 
  

 - 11 - 

 12.5 The Executive will, during and after the Executive’s employment with Angiotech, assist Angiotech
as much as is reasonably necessary to establish, protect, and enforce Work Product and Intellectual Property, provided that Angiotech: 
  

	 	(a)	reimburses the Executive for all reasonable expenses thereby incurred; and 

  

	 	(b)	provides reasonable compensation to the Executive for efforts thereby expended after the end of the Executive’s employment with Angiotech.

 12.6 The Executive irrevocably waives in favour of Angiotech any and all moral rights that the Executive may have with respect
to any Work Product, including, without limitation, the right to attribution of authorship, the right to restrain or claim damages for any distortion, mutilation, modification, or enhancement of any Work Product, and the right to retain, use, or
reproduce any Work Product in any context and in connection with any product, service, or business, and Angiotech may use or alter any Work Product, as Angiotech sees fit, in its sole discretion. 
 12.7 A concept, method, process, technology, invention, development or other work developed by the Executive may be determined to be a Non-Angiotech
Invention under paragraph 12.1(b)(ii) if: 
  

	 	(a)	subject to paragraph 12.11, the Executive immediately and fully discloses that concept, method, process, technology, invention, development, or other work, in writing,
to both Angiotech’s General Counsel and its Human Resources Department; and 

  

	 	(b)	the Board determines, in its sole discretion, that the concept, method, process, technology, invention, development, or other work is a Non-Angiotech Invention,
provided that, for greater certainty, the Board may determine that a concept, method, process, technology, invention, development, or other work is not a Non-Angiotech Invention if one or more of the following apply to that concept, method, process,
technology, invention, development, or other work: 

  

	 	(i)	it was developed by the Executive during the Executive’s business time for Angiotech, or using any equipment, facilities, materials, personnel, trade secrets, or
Confidential Information of Angiotech; 

  

	 	(ii)	it relates to the Business of Angiotech or to Angiotech’s current or anticipated research or development; or 

  

	 	(iii)	it is otherwise derived from any work performed by the Executive for Angiotech. 

 12.8 If the disclosure of any Non-Angiotech Invention in Appendix B would violate any obligation of confidentiality that the Executive owes to a third party, Appendix B must instead include (to
the extent it does not violate that obligation of confidentiality) a brief description of such Non-Angiotech Invention, a list of all third parties to whom the Non-Angiotech Invention belongs, and the reason full disclosure is prohibited.

  

 - 12 - 

 12.9 If, during the Executive’s employment with Angiotech, the Executive incorporates any Non-Angiotech
Invention into any product, process, service, equipment, or facilities of Angiotech, the Executive will grant Angiotech a non-exclusive, royalty-free, perpetual, and irrevocable worldwide licence (including the right to sublicense) to make, have
made, use, offer to sell, sell, import, copy, distribute, modify, and otherwise practise and exploit such Non-Angiotech Invention as part of Angiotech’s product, process, service, equipment, or facilities (to the extent the Executive is legally
entitled to grant such licence or rights to Angiotech). 
 12.10 Subject to paragraph 12.11, while the Executive is employed by Angiotech, the
Executive will, immediately, fully disclose to Angiotech, in writing, all items, methods, technologies, inventions, and other works, of any nature, developed, conceived, or reduced to practice by the Executive, whether alone or with others, that
constitute Work Product or that otherwise relate to the Business of Angiotech. 
 12.11 If the disclosure of any item, concept, method, process,
technology, invention, development, or other work under paragraph 12.7 or 12.10 would violate any obligation of confidentiality that the Executive may owe to a third party, the Executive will, instead, immediately disclose to Angiotech (to the
extent it does not violate that obligation of confidentiality) a description of such item, method, technology, invention, or other work, a list of all third parties to whom it belongs, and full and complete reasons why full disclosure is prohibited.

 12.12 At the end of the Executive’s employment, the Executive will immediately return to Angiotech all Work Product and all other
property of Angiotech, including, without limitation, all medical devices, medical implants, and other products, all computers, telephones, personal digital assistants, and other equipment, and all Confidential Information, proprietary or licensed
computer programs, customer lists, customer data, books, records, forms, specifications, formulas, data, data processes, designs, papers, and writings relating to the Business of Angiotech, and any copies thereof, in the Executive’s possession
or under the Executive’s control. For greater certainty, the Executive will not retain any copies of any such property, and will immediately provide to Angiotech all passwords and other security devices required to enable access to such
property, and any licences granted to the Executive for the use of any such property will be immediately revoked on the Last Day of Employment. 
  

	13.	CONFIDENTIALITY 

 13.1 In this Agreement:

 “Confidential Information” means all information and materials of Angiotech, and its customers, clients,
vendors, consultants, and other parties with which Angiotech does business that is not generally known by or freely available to the public, including, without limitation, information pertaining to biological materials and their progeny and
derivatives, drug formulations, pre-clinical and clinical trials (abandoned or undertaken), work product, inventions, discoveries, concepts, ideas, know-how, plans, strategies, developments, technologies, computer programs, formulas, algorithms,
compilations, data, devices, designs, prototypes, drawings, diagrams, schematics, practices, processes,

  

 - 13 - 

 
methods, products, procedures, manuals, techniques, customer and supplier lists and data, price lists, policies, records, forms, specifications, trade secrets, research, laboratory notes,
analysis, reports, studies, budgets, projections, bids, costs, financial reports and information, financing materials, training programs, sales and marketing programs, plans and strategies, regulatory filings, and correspondence, whether or not
expressed in tangible form, and in any format: 
 (a) relating to the Business of Angiotech; or 
 (b) otherwise relating to Angiotech’s past, present, or future businesses, properties, research, products, or services. 
 13.2 Unless the Executive can demonstrate that information or materials in issue (including Work Product) is generally known by or freely available to the
public through no fault of the Executive or any person with whom the Executive is, directly or indirectly, affiliated or related, then the information or material will be presumed and deemed to be Confidential Information. 
 13.3 Unless and until any Confidential Information ceases to be confidential under paragraph 13.2, the Executive will forever: 
  

	 	(a)	keep private and maintain in strict confidence such Confidential Information; and 

  

	 	(b)	not, directly or indirectly, use, disseminate, disclose, lecture on, publish, duplicate, or summarize the Confidential Information, in whole or in part, except to the
extent: 

  

	 	(i)	required by law, but subject to paragraph 13.5; 

  

	 	(ii)	required to enable the Executive to discharge the Executive’s duties and responsibilities under this Agreement; or 

  

	 	(iii)	that Angiotech first consents in writing, and the Executive complies with all terms and conditions imposed by Angiotech in the consent. 

 13.4 The Executive will forever observe the terms of all agreements regarding confidentiality between Angiotech and others, except to the extent:

  

	 	(a)	required by law, but subject to paragraph 13.5; or 

  

	 	(b)	that Angiotech first consents in writing, and the Executive complies with all terms and conditions imposed by Angiotech in the consent. 

 13.5 If the Executive reasonably believes that the Executive is required by law to disclose anything otherwise prohibited under paragraphs 13.3 and
13.4: 
  

	 	(a)	the Executive will immediately notify Angiotech in writing of all material particulars of the situation; 

  

 - 14 - 

	 	(b)	if Angiotech does not agree that disclosure is required by law, the Executive will not make any disclosure unless an arbitrator under Part 21 or a Court of
competent jurisdiction orders otherwise; and 

  

	 	(c)	in any event, the Executive will take all lawful steps to ensure that any disclosure required by law is subject to a protective order of confidentiality.

 13.6 Nothing in this Agreement limits or supersedes any other right or remedy that Angiotech may have, under applicable law,
with respect to the protection of Confidential Information. 
  

	14.	TERMINATION 

 14.1 In this Agreement:

  

	 	(a)	“Angiotech US” means Angiotech Pharmaceuticals (US), Inc., a corporation incorporated under the laws of the State of Washington;

  

	 	(b)	“Change of Control” means the occurrence of any one or more of the following: 

  

	 	(i)	a change in the composition of the Board as a result of which fewer than one-half of the incumbent directors are individuals who were directors 12 months before the
change; but excluding any such change in the composition of the Board made with the approval of the Board as it was constituted immediately before the change; 

  

	 	(ii)	the acquisition or aggregation by any person, entity, or group of persons or entities acting jointly or in concert (“Acquiror”) of beneficial ownership or
control of Voting Securities (including, without limitation, the power to vote or direct the voting thereof), as a result of which the Acquiror and/or associates and/or affiliates of the Acquiror become entitled to cast or direct the casting of 50%
or more of the votes attached to all of the outstanding Voting Securities which may be cast to elect directors (regardless of whether a meeting has been called to elect directors); but excluding a change in the relative beneficial ownership of the
Acquiror in Voting Securities resulting solely from a reduction in the aggregate number of the outstanding Voting Securities, unless and until the Acquiror increases, in any manner, directly or indirectly, the Acquiror’s beneficial ownership or
control of Voting Securities (after which the Acquiror and/or associates and/or affiliates of the Acquiror are entitled to cast or direct the casting of 50% or more of the votes attached to all of the outstanding Voting Securities which may be cast
to elect directors); 

  

	 	(iii)	 the disposition of all or substantially all of the assets or business of Angiotech or Angiotech US pursuant to a merger, consolidation, or other
transaction, unless the common shares of the entity or entities that succeed to the business of Angiotech, and any other shares entitled to vote for the election of directors of such entity or entities, are beneficially owned or

  

 - 15 - 

	 	 
controlled by persons, entities, or groups of persons or entities acting jointly or in concert who held beneficial ownership or control of Voting Securities immediately before such merger,
consolidation, or other transaction, in substantially the same proportion as they owned such Voting Securities; 

  

	 	(iv)	the adoption of a resolution to wind-up, dissolve, or liquidate Angiotech or Angiotech US; or 

  

	 	(v)	a consolidation, merger, amalgamation, arrangement, or other reorganization or acquisition of Angiotech or Angiotech US, as a result of which the holders of Voting
Securities immediately before the completion of such transaction hold less than 50% of the outstanding common shares and other shares entitled to vote for the election of directors of the successor corporation after completion of the transaction;

  

	 	(c)	“Good Reason” means the occurrence of any one or more of the following without the Executive’s written consent: 

  

	 	(i)	a material reduction in the Executive’s title, office, authority, or duties or responsibilities of employment; 

  

	 	(ii)	one or more reductions in the Executive’s Base Salary, or in the Executive’s target bonus opportunity under the Bonus Plan, in the cumulative amount of 5% or
more within a 12 month period, or a material reduction in the Executive’s benefits or perquisites, if such reductions: 

  

	 	(A)	are not made in conjunction with similar reductions for comparably situated executive employees of Angiotech, or 

  

	 	(B)	are made in conjunction with similar reductions for comparably situated executive employees of Angiotech at the time of, or within 24 months after, a Change of Control;

  

	 	(iii)	a change in the Executive’s principal place of employment by a distance of 80 kilometers or more, unless the new principal place of employment is within 80
kilometers of the Executive’s then current residence; 

  

	 	(iv)	a material breach by Angiotech of a fundamental term of this Agreement; or 

  

	 	(v)	an Unapproved Change of Control; 

 but does not include the Executive being placed on paid leave for up to 30 days pending the determination by Angiotech of whether there is or may be just cause to terminate the Executive’s employment; 
  

 - 16 - 

	 	(d)	“Last Day of Employment” means: 

  

	 	(i)	immediately on receipt of the Notice of Termination if the Executive’s employment is terminated by Angiotech for just cause; 

  

	 	(ii)	the effective date of the Notice of Termination if the Executive’s employment is terminated by the Executive without Good Reason; or 

  

	 	(iii)	immediately on receipt of the Notice of Termination if the Executive’s employment is terminated by Angiotech for any reason other than for just cause, or is
terminated by the Executive for Good Reason, except in circumstances where the Employment Standards Act (British Columbia) or other applicable employment standards legislation requires this to be at the end of the period of notice prescribed
thereunder, in which case it will be at the end of the period of notice; 

 or such later date as may otherwise be
agreed between Angiotech and the Executive; 
  

	 	(e)	“Notice of Termination” means a written notice of termination of the Executive’s employment with Angiotech; 

  

	 	(f)	“Unapproved Change of Control” means a Change of Control that: 

  

	 	(i)	is recommended against to the Board by Angiotech’s Chief Executive Officer in office immediately before the Change of Control; or 

  

	 	(ii)	is not approved, supported, or recommended by the Board as it was constituted immediately before the Change of Control; 

  

	 	(g)	“Voting Securities” means common shares of Angiotech and any other shares entitled to vote for the election of directors of Angiotech.

 14.2 Angiotech may terminate the Executive’s employment at any time by giving a Notice of Termination to the Executive.

 14.3 The Executive may terminate the Executive’s employment for Good Reason if Angiotech fails to cure the circumstances which gave the
Executive Good Reason within 20 days of the Executive giving Angiotech written notice identifying those circumstances (provided that such notice must be given within 90 days after the Executive knows, or should have known, of those circumstances),
by the Executive giving a Notice of Termination to Angiotech after the expiration of that 20-day period. Except in accordance with this paragraph, the Executive may not otherwise terminate the Executive’s employment for Good Reason. 

14.4 The Executive may terminate the Executive’s employment at any time without Good Reason by giving a Notice of Termination to Angiotech,
providing Angiotech with 60 days’ notice of the termination of the Executive’s employment, which Angiotech may waive in whole or in part. 
  

 - 17 - 

 14.5 If the Executive’s employment is terminated by the Executive without Good Reason, Angiotech will:

  

	 	(a)	pay any unpaid Base Salary earned by the Executive up to the Last Day of Employment, and, if Angiotech has waived the notice period or any part of it under paragraph
14.4, the equivalent Base Salary the Executive would otherwise have earned during the notice period; 

  

	 	(b)	pay the balance of any outstanding payments under the Bonus Plan that are or were payable to the Executive on or before the last day of the notice period; and

  

	 	(c)	make any payments due under paragraph 9.3(b) or 10.1(a); 

 and Angiotech will have no further obligation to the Executive under this Agreement. In particular, the Executive will be deemed not to have earned any payment under the Bonus Plan either in regard to the
fiscal year in which the termination of employment occurs, or in regard to any previous fiscal year, to the extent such payment has not become payable to the Executive as of the last day of the notice period. 
 14.6 If the Executive’s employment is terminated by Angiotech for just cause, Angiotech will: 
  

	 	(a)	pay any unpaid Base Salary earned by the Executive up to the Last Day of Employment; 

  

	 	(b)	pay the balance of any outstanding payments under the Bonus Plan that are or were payable to the Executive on or before the Last Day of Employment; and

  

	 	(c)	make any payments due under paragraph 9.3(b) or 10.1(a); 

 and Angiotech will have no further obligation to the Executive under this Agreement. In particular, the Executive will be deemed not to have earned any payment under the Bonus Plan either in regard to the
fiscal year in which the termination of employment occurs, or in regard to any previous fiscal year, to the extent such payment has not become payable to the Executive as of the Last Day of Employment. 
 14.7 If the Executive’s employment is terminated by Angiotech for any reason other than for just cause or is terminated by the Executive for Good
Reason, and paragraph 14.8 does not apply, Angiotech will: 
  

	 	(a)	pay any unpaid Base Salary earned by the Executive up to the Last Day of Employment; 

  

	 	(b)	pay a lump sum amount as severance compensation, equivalent to the total of: 

  

	 	(i)	12 months of Base Salary, and 

  

 - 18 - 

	 	(ii)	an additional two months of Base Salary for each full year of employment completed by the Executive, 

 up to a combined maximum of 24 months of Base Salary; 
  

	 	(c)	pay a further lump sum amount as compensation for loss of any benefits made available to the Executive or the Executive’s immediate family, including any benefit
coverage under any health, dental, life insurance, disability, or other insurance or employee benefits plan, any RRSP contributions or other retirement benefits, and any other perquisites of employment, including any automobile allowance, automobile
lease, financial or tax planning services, memberships, or otherwise, in the total amount of: 

  

	 	(i)	$24,000, plus 

  

	 	(ii)	an additional $2,000 for each full year of employment completed by the Executive, 

 up to a combined maximum of $48,000; 
  

	 	(d)	pay the balance of any payments which may be due to the Executive under the Bonus Plan, including, if applicable, a prorated payment under the Bonus Plan earned in
respect of the fiscal year in which the Executive’s employment is terminated, as and when determined by the Board; and 

  

	 	(e)	make any payments due under paragraph 9.3(b) or 10.1(a). 

 14.8 If, at the time of, or within 24 months after, a Change of Control, the Executive’s employment is terminated by Angiotech for any reason other than for just cause or is terminated by the
Executive for Good Reason, Angiotech will: 
  

	 	(a)	pay any unpaid Base Salary earned by the Executive up to the Last Day of Employment; 

  

	 	(b)	pay a lump sum amount as severance compensation, equivalent to the total of: 

  

	 	(i)	24 months of Base Salary, and 

  

	 	(ii)	an additional two months of Base Salary for each full year of employment completed by the Executive, 

 up to a combined maximum of 36 months of Base Salary; 
  

	 	(c)	 pay a further lump sum amount as compensation for loss of any benefits made available to the Executive or the Executive’s immediate family,
including any benefit coverage under any health, dental, life insurance, disability, or other

  

 - 19 - 

	 	 
insurance or employee benefits plan, any RRSP contributions or other retirement benefits, and any other perquisites of employment, including any automobile allowance, automobile lease, financial
or tax planning services, memberships, or otherwise, in the total amount of: 

  

	 	(i)	$48,000, plus 

  

	 	(ii)	an additional $2,000 for each full year of employment completed by the Executive, 

 up to a combined maximum of $72,000; 
  

	 	(d)	pay the balance of any payments which may be due to the Executive under the Bonus Plan, including, if applicable, a prorated payment under the Bonus Plan earned in
respect of the fiscal year in which the Executive’s employment is terminated, as and when determined by the Board; 

  

	 	(e)	pay a further lump sum amount, equal to two times the greater of: 

  

	 	(i)	the average of the payments made to the Executive under the Bonus Plan in each of the two immediately preceding fiscal years, and 

  

	 	(ii)	the amount of the Executive’s target bonus opportunity under the Bonus Plan for the fiscal year in which the Executive’s employment is terminated;

  

	 	(f)	if the Executive holds any stock options, securities, grants, or awards under any stock option agreement, plan, or program, or other equity-based incentive plan or
program, which are not vested as of the Last Day of Employment in accordance with the provisions of the applicable agreement, plan, or program referred to in paragraph 8.1 (and if vesting does not accelerate under those provisions), pay a
further lump sum amount equivalent to the amount the Executive would have received if the Executive had been able to exercise those stock options, securities, grants, or awards under the applicable agreement, plan, or program, and sell the shares or
underlying securities resulting from their exercise at a price equal to the closing price of such shares or underlying securities on the Toronto Stock Exchange as of the Last Day of Employment; 

  

	 	(g)	make any payments due to the Executive under paragraph 9.3(b) or 10.1(a); 

  

	 	(h)	 in the case of a Change of Control that is not an Unapproved Change of Control, if any payment, award, benefit, or distribution (or any acceleration of
any payment, award, benefit, or distribution) made by Angiotech under this Agreement or otherwise to or for the benefit of the Executive is subject to excise tax under Section 4999 of the Code (referred to in this paragraph 14.8(h)
as the “Excise Tax”), and the reduction of the amounts payable to the Executive under this Agreement to the maximum amount that could be paid to the Executive

  

 - 20 - 

	 	 
without triggering the Excise Tax (“Safe Harbor Cap”) would provide the Executive with a greater after tax amount than if such amounts were not reduced, then the amounts payable to the
Executive under this Agreement will be reduced to the Safe Harbor Cap (but not below zero), provided that: 

  

	 	(i)	the reduction of the amounts payable hereunder, if applicable, will be made by reducing the payments under paragraph 14.8(b); and 

  

	 	(ii)	if the reduction of the amounts payable would not result in a more favourable after tax consequence to the Executive, no amounts payable under this Agreement will be
reduced; and 

  

	 	(i)	in the case of a Change of Control that is an Unapproved Change of Control, if any payment, award, benefit, or distribution (or any acceleration of any payment, award,
benefit, or distribution) made by Angiotech under this Agreement or otherwise to or for the benefit of the Executive (but without regard to any additional payments required under this paragraph 14.8(i)), is subject to excise tax under
Section 4999 of the Code, or if any interest or penalties are incurred by the Executive with regard to such excise tax (such excise tax, together with any such interest and penalties, being collectively referred to in this
paragraph 14.8(i) as the “Excise Tax”), Angiotech will pay the Executive an additional payment (“Gross-Up Payment”) such that after payment by the Executive of all taxes (including any Excise Tax) imposed on the Gross-Up
Payment, the Gross-Up Payment will be the sum of: 

  

	 	(i)	the Excise Tax, and 

  

	 	(ii)	the product of any deductions disallowed because of the inclusion of the Gross-Up Payment in the Executive’s adjusted gross income and the highest applicable
marginal rate of federal income taxation for the calendar year in which the Gross-Up Payment is made. 

 14.9 If Angiotech’s
shares cease to be listed on the Toronto Stock Exchange, the reference to the Toronto Stock Exchange in paragraph 14.8(f) will be deemed to be replaced with a reference to the NASDAQ or to such other stock exchange or quotation and trade reporting
system, if any, on which the greatest trading volume in Angiotech’s common shares occurs. 
 14.10 Before any payments are made to the
Executive under 
  

	 	(a)	paragraph 14.7(b) or (c), or 

  

	 	(b)	paragraph 14.8(b), (c), (e), (f) or (i) 

 the Executive will execute and deliver to Angiotech a release in the form attached as Appendix A or in a similar form prepared by Angiotech. 
 14.11 Angiotech’s obligation to make any payments under 
  

 - 21 - 

	 	(a)	paragraph 14.7(b) to (d), or 

  

	 	(b)	paragraph 14.8(b) to (f) and (i)

 is
conditional on the Executive’s ongoing compliance with all applicable post-employment obligations of the Executive under this Agreement, including, without limitation, the Executive’s obligations under Parts 3, 11, 12, and 13. If the
Executive breaches any such obligation, the Executive will immediately disgorge and repay Angiotech any such payments received and will be disentitled to any further such payments, without limiting, diminishing, or affecting any other damages,
losses, costs, or expenses for which the Executive may be liable for any breach of this Agreement. 
 14.12 The Executive will not be required
to seek other employment to be eligible to receive any payments payable under this Agreement after termination of the Executive’s employment, and no amount will be set-off against any such payments on account of any remuneration or benefit that
the Executive may receive as a result of any other employment the Executive may obtain. 
 14.13 If the Executive dies, 
  

	 	(a)	the Executive’s estate will be entitled to receive: 

  

	 	(i)	any unpaid Base Salary earned up to the date of the Executive’s death; 

  

	 	(ii)	the balance of any payments which may be due to the Executive under the Bonus Plan as of the date of the Executive’s death, including a prorated payment under the
Bonus Plan earned in respect of the fiscal year in which the Executive’s death occurs, if applicable, as and when determined by the Board; and 

  

	 	(iii)	any amounts due to the Executive under paragraph 9.3(b) or 10.1(a) as of the date of the Executive’s death; 

  

	 	(b)	any outstanding stock options or other grants or awards held by the Executive, as of the date of the Executive’s death, under any stock option agreement, plan, or
program, or other equity-based incentive plan or program, will continue to be governed by the provisions of the applicable agreement, plan, or program; and 

  

	 	(c)	Angiotech will have no other or further obligation to the Executive or the Executive’s estate. 

 14.14 If, through no fault of the Executive, the Executive ceases to be legally eligible to work in Canada: 
  

	 	(a)	the Executive will cooperate with Angiotech and use best efforts to attempt to restore the Executive’s eligibility to work in Canada; and 

 

 - 22 - 

	 	(b)	if, after taking the steps under subparagraph (a), the Executive and Angiotech are unable to restore the Executive’s eligibility to work in Canada, the Executive
will be entitled to receive payments under paragraph 14.7 as if the Executive’s employment had been terminated by Angiotech without just cause, and the Last Day of Employment will be deemed to be the date on which the Executive ceased to be
eligible to work in Canada. 

 14.15 The provisions of this Part 14 are fair and reasonable and constitute Angiotech’s
only obligation to provide notice of termination, severance pay, compensation under employment standards legislation, and related compensation upon the termination of the Executive’s employment without just cause, including, without limitation,
damages in lieu of reasonable notice of termination, loss of opportunity to exercise or acquire stock options, securities, grants, or awards under any stock option agreement, plan, or program, or other equity-based incentive plan or program, damage
or injury to reputation, damages for bad faith or otherwise pertaining to the manner of dismissal, psychological damage or injury, loss of opportunity to receive payments under the Bonus Plan or any other incentive compensation, lost insurance
benefits, negligence or other tort claims, or otherwise. In particular, Angiotech will have no greater obligation than specified in this Part 14 if, after the Last Day of Employment, the Executive becomes sick, ill, disabled, or otherwise
unable to work, or dies. 
  

	15.	ENFORCEMENT 

 15.1 The restrictions in
Parts 11, 12, and 13 are necessary for the protection of Angiotech’s interests and the Business of Angiotech, are reasonable and valid, and will not prevent the Executive from pursuing a livelihood, and the Executive irrevocably waives all
defences to their enforcement. 
 15.2 In addition to any and all other rights and remedies available to Angiotech, an injunction is the only
effective and meaningful remedy for any breach of the Executive’s obligations under Parts 3, 11, 12, and 13, and Angiotech would suffer irreparable harm and injury in the event of any such breach. Accordingly, Angiotech may, without having
to prove actual or potential damages, loss, injury, or harm, apply for and obtain injunctive relief from any Court of competent jurisdiction, including, without limitation, an interim, interlocutory, or permanent injunction, to enforce any of these
provisions upon their breach or threatened breach. 
  

	16.	SECTION 409A OF INTERNAL REVENUE CODE 

 16.1 Subject to paragraph 16.2, if, on the Executive’s Last Day of Employment, the Executive is a “specified employee” as defined in Section 409A of the Code, no payment or benefit will be provided under this
Agreement until the earlier of: 
  

	 	(a)	six months after the Last Day of Employment; or 

  

	 	(b)	the date of the Executive’s death; 

 except
as may otherwise be required under the Employment Standards Act (British Columbia) or other applicable employment standards legislation. 
  

 - 23 - 

 16.2 Paragraph 16.1 will apply: 
  

	 	(a)	only to the extent required to avoid causing the Executive to incur any additional income tax or interest under Section 409A of the Code or any regulation
or US Treasury Department guidelines promulgated thereunder; and 

  

	 	(b)	despite any other provision of this Agreement. 

 16.3 If any provision of this Agreement (or any award of compensation hereunder) would cause the Executive to incur any additional income tax or interest under Section 409A of the Code or any regulation or US Treasury Department
guidelines promulgated thereunder: 
  

	 	(a)	Angiotech will propose any changes to this Agreement that Angiotech may determine to be necessary to avoid causing the Executive to incur such additional income tax or
interest, provided that any such changes will give effect, to the extent practicable, to the intent of the provisions of this Agreement without violating the provisions of Section 409A of the Code; and 

  

	 	(b)	the Executive’s agreement to any such changes proposed by Angiotech will not be unreasonably withheld. 

  

	17.	EXECUTIVE’S REPRESENTATIONS 

 17.1 In
this Agreement: 
 “Previous Employer” means any previous employer of the Executive, or any entity for which the
Executive has worked or to which the Executive has provided services. 
 17.2 The Executive represents and warrants that: 
  

	 	(a)	the Executive is legally eligible to work in Canada; 

  

	 	(b)	the Executive has no obligation to assign any rights, title, or interest in or to any Work Product or Intellectual Property to any third party that conflicts or is
inconsistent with the Executive’s obligations under this Agreement; 

  

	 	(c)	the Executive has no other employment, work, consultancy, engagements, undertakings, or other relationship that could restrict or impair the performance of the
Executive’s duties and responsibilities under this Agreement; 

  

	 	(d)	the Executive has complied and is in compliance with any enforceable covenants in any agreement with any Previous Employer; 

  

	 	(e)	the Executive has kept confidential and not disclosed or made available to Angiotech any confidential information of any Previous Employer; 

  

 - 24 - 

	 	(f)	upon ending the Executive’s employment with, or ceasing to work for or provide services to, any Previous Employer, the Executive did not take or remove anything
proprietary to that Previous Employer; 

  

	 	(g)	the Executive is not aware of any outstanding or potential claims or demands which have been or may be brought against the Executive in relation to the Executive’s
employment or other work for, or services provided to, any Previous Employer; 

  

	 	(h)	all items, methods, technology, inventions, and other works of any nature developed or provided by the Executive to Angiotech: 

  

	 	(i)	are or will be original to the Executive, except to the extent otherwise disclosed to Angiotech, and 

  

	 	(ii)	do not, and will not when used or exploited by Angiotech or its contractors or customers, infringe any rights of the Executive or any third party;

  

	 	(i)	all Non-Angiotech Inventions as of the date of this Agreement are fully disclosed in Appendix B, except as provided in paragraph 12.8, and all information
disclosed in Appendix B is true and correct; and 

  

	 	(j)	the execution, delivery, and performance of this Agreement does not and will not otherwise conflict with or result in the violation or breach of any order, judgment,
injunction, contract, agreement, commitment, or other arrangement to which the Executive is a party or by which the Executive is bound. 

 17.3 The Executive: 
  

	 	(a)	agrees that Angiotech has entered into this Agreement relying on the representations and warranties in paragraph 17.2; and 

  

	 	(b)	will indemnify and save harmless Angiotech from and against any and all claims, causes of action, damages, losses, costs, and expenses, including reasonable legal fees,
taxes, and disbursements, arising from the incorrectness of, or any breach of, any representation or warranty in paragraph 17.2. 

 17.4 The Executive: 
  

	 	(a)	will continue to comply with any enforceable covenants in any agreement with any Previous Employer; and 

  

	 	(b)	will continue to maintain in confidence any confidential information of any Previous Employer, and will not disclose or make available to Angiotech any such
confidential information of a Previous Employer. 

  

 - 25 - 

	18.	GOVERNING LAW AND FORUM 

 18.1 This
Agreement is deemed to be made in British Columbia, and will be governed by and construed and interpreted in accordance with the laws of British Columbia and laws of Canada applicable therein. 
 18.2 Subject to Part 21, if Angiotech commences a proceeding in the Courts of British Columbia to interpret or enforce any term of this Agreement or to
resolve any dispute under it, the Executive will irrevocably attorn to the jurisdiction of the Courts of British Columbia in connection therewith, and the Courts of British Columbia will have exclusive jurisdiction in connection therewith.

  

	19.	NOTICES 

 19.1 All notices and other
communications required or permitted to be given under this Agreement will be in writing, and will be delivered or sent by registered mail to the party entitled to receive them, as follows: 
  

	 	(a)	JEFFREY M. GROSS 

 3275 West 22nd Street 
 Vancouver, BC V6L 1N1 
  

	 	(b)	ANGIOTECH PHARMACEUTICALS, INC. 

 1618 Station Street 
 Vancouver, BC V6A 1B6 

					
		 	Attention:	 	 David D. McMasters,
 General
Counsel and Senior Vice President, Legal

 19.2 Either party may notify the other in writing of a change of address to which
notices will thereafter be given. 
  

	20.	SEVERABILITY AND WAIVER 

 20.1 Each
provision of this Agreement is a separate obligation and is severable from all other such obligations, and if any of them is held by an arbitrator under Part 21 or by a Court to be invalid or unenforceable, this Agreement will be construed by
limiting, restricting, or reducing the application or scope of the applicable provision or provisions, to the extent necessary to comply with applicable law then in effect. 
 20.2 In this Agreement: 
  

	 	(a)	a waiver of any provision of this Agreement will not be binding unless in writing and signed by both parties; 

  

	 	(b)	a failure to exercise or a delay in exercising any right or remedy under this Agreement will not be deemed to be a waiver of that right or remedy; and

  

 - 26 - 

	 	(c)	a waiver or excuse by either party of any default or breach by the other party of any provision of this Agreement will not waive that party’s rights in respect of
any continuing or subsequent default or breach, or affect the rights of that party in respect of any such continuing or subsequent default or breach. 

  

	21.	DISPUTE RESOLUTION 

 21.1 Before
initiating any legal proceedings, the parties will attempt to resolve all disputes concerning the interpretation, application or enforcement of any term of this Agreement, any alleged breach of or non-compliance with this Agreement, or otherwise
arising out of or in connection with this Agreement or any aspect of the Executive’s employment with Angiotech or the termination of that employment, by mediated negotiation, and will use their best efforts to agree on a mediator and to resolve
any disputes by mediation. 
 21.2 If a dispute referred to in paragraph 21.1 cannot be resolved by mediation within 15 days after one of the
parties notifies the other of an intention to mediate the dispute, or if the parties are unable to agree on a mediator within 10 days of such notice, either party may give notice to the other party of its intention to refer the dispute to binding
arbitration. 
 21.3 A dispute that is referred to binding arbitration under paragraph 21.2 will be finally resolved by a single arbitrator
under the Commercial Arbitration Act (British Columbia) (“CAA”). 
 21.4 If the parties are unable to agree to an
arbitrator within 10 days of the notice referring the dispute to arbitration, either party may apply to the Supreme Court of British Columbia (“Supreme Court”) for the appointment of a single arbitrator under the CAA. 
 21.5 Immediately after the arbitration has commenced, the parties will agree under section 35 of the CAA to exclude the jurisdiction of the Supreme
Court under sections 31, 33 and 34 of the CAA. 
 21.6 The arbitration will be in Vancouver, British Columbia. 
 21.7 The arbitrator will: 
  

	 	(a)	subject to the provisions of this Agreement, apply the Domestic Commercial Arbitration Rules of Procedure of the British Columbia International Commercial Arbitration
Centre with any modifications as may be agreed to by the parties, or such other rules of procedure as may otherwise be agreed to by the parties; 

  

	 	(b)	not have the authority or jurisdiction to award: 

  

	 	(i)	punitive or aggravated damages, or damages for any intangible loss or injury, including damage or injury to reputation, damages for bad faith or otherwise pertaining to
the manner of dismissal, or psychological damage or injury, or 

  

 - 27 - 

	 	(ii)	injunctive relief, specific performance, or any other equitable remedy; 

  

	 	(c)	conduct the arbitration proceeding within 30 days of being appointed; and 

  

	 	(d)	render a decision within 30 days of the completion of the arbitration proceeding. 

 21.8 The award of the arbitrator will be final and binding, and any order, ruling, or award made by the arbitrator will not be questioned, reviewed, restrained, amended, or set aside by the Supreme Court,
except for arbitral error under section 30 of the CAA. 
 21.9 Despite paragraph 21.3: 
  

	 	(a)	either party may, before or after an arbitration has commenced, apply to the Supreme Court for interim relief under section 15(4) of the CAA; and

  

	 	(b)	Angiotech may, before or after an arbitration has commenced, apply to any Court of competent jurisdiction for injunctive relief under paragraph 15.2.

  

	22.	INDEPENDENT LEGAL ADVICE 

 22.1
Angiotech’s lawyers prepared this Agreement. The Executive was asked to obtain independent legal advice before signing this Agreement, and represents by signing it that such advice has been obtained. 
  

	23.	ENUREMENT AND ASSIGNMENT 

 23.1 This
Agreement will enure to the benefit of and be binding on the parties and their respective heirs, executors, administrators, successors, and permitted assigns. 
 23.2 The Executive will not assign this Agreement without Angiotech’s prior written consent. 
  

	24.	INTERPRETATION 

 24.1 In this Agreement:

  

	 	(a)	“Angiotech” includes, as the context may require, its affiliates, subsidiaries, associated companies, successors, and assigns;

  

	 	(b)	“Board” means the Board of Directors of Angiotech; 

  

	 	(c)	“Code” means United States Internal Revenue Code of 1986, as amended; 

  

	 	(d)	“day” means calendar day, unless otherwise specified; 

  

	 	(e)	“IRS” means Internal Revenue Service. 

 24.2 All monetary amounts expressed in this Agreement are in Canadian currency, unless otherwise specified. 
  

 - 28 - 

 24.3 Any reference in this Agreement to an enactment will be deemed to be a reference to such enactment as
it may be amended or replaced from time to time, and any reference to a particular provision of an enactment will include a reference to an equivalent provision, if the enactment is amended or replaced. 
 24.4 Any rule of interpretation that any ambiguity is to be resolved against the drafting party is not applicable to this Agreement. 
  

	25.	ENTIRE AGREEMENT 

 25.1 This document
contains the entire agreement between the parties with respect to the Executive’s employment, and cancels and supersedes all prior agreements and discussions between them relating to the Executive’s employment. 
 25.2 Except as provided in this Agreement, no amendment or variation of the terms of this Agreement will be effective or binding unless in writing and
signed by both parties. 
 TO EVIDENCE THEIR AGREEMENT the parties have executed this Agreement on the dates appearing below. 
  

									
	SIGNED, SEALED AND DELIVERED by	 	)	 		 		 	
	JEFFREY M. GROSS in the presence of:	 	)	 		 		 	
		 	)	 		 		 	
	  
	 	)	 		 		 	
	(Signature of Witness)	 	)	 		 	  
	 	
		 	)	 		 	JEFFREY M. GROSS	 	
	  
	 	)	 		 		 	
	(Print Name of Witness)	 	)	 		 		 	
		 	)	 		 		 	
	  
	 	)	 		 		 	
	(Address of Witness)	 	)	 		 		 	
		 	)	 		 		 	
	  
	 	)	 		 		 	
	(Occupation of Witness)	 	)	 		 		 	
		 	)	 		 		 	
	  
	 	)	 		 		 	
	(Date)	 		 		 		 	

			
	ANGIOTECH PHARMACEUTICALS, INC.
		
	By:	 	
	  

	Authorized Signatory
		
	Date:	 	  

  

 - 30 - 

 APPENDIX A 
 Form of Release 
 FULL AND FINAL RELEASE 

 AND PROMISE NOT TO INITIATE LEGAL ACTION 
 I, —, in consideration of the gross sum of $—
 (less required statutory deductions and withholdings), the receipt and sufficiency of which is hereby acknowledged, voluntarily agree: 
 1. Not to initiate any type of legal or regulatory action, and to release and forever discharge Angiotech Pharmaceuticals, Inc. (“Angiotech”), its affiliates and subsidiaries, its and their successors and assigns, and its and
their present and former officers, directors, employees, shareholders, partners, agents, and otherwise, as the case may be (collectively, the “Releasees”), of and from any and all causes of action, suits, contracts, complaints, claims,
damages, costs, and expenses of any nature or kind whatsoever, known or unknown (collectively, “Claims”), which as against the Releasees, and any of them, I have ever had, now have, or at any time hereafter I and my personal
representatives can, shall or may have, arising out of any cause, matter or thing, including, without limiting the generality of the foregoing: 
  

	 	(a)	Claims arising directly or indirectly out of my hiring or the termination of my employment with Angiotech, or in any other way relating directly or indirectly to my
employment with Angiotech; 

  

	 	(b)	Claims relating directly or indirectly to the loss of disability insurance, life insurance, share options, bonuses, incentive compensation, shares, equity-based
compensation or incentives, pension, RRSP contributions, and any other form of compensation, benefit, or perquisite of my employment with Angiotech; 

  

	 	(c)	Claims for disability or sickness, or for insurance benefits relating directly or indirectly to such Claims; and 

  

	 	(d)	Claims arising under any Federal or Provincial statute, including specifically claims under the [names of applicable statutes to be inserted by Angiotech
when the employment relationship is terminated]. 

 2. That neither the settlement nor anything contained herein is
an admission of any liability by the Releasees, or any of them, by whom liability is expressly denied. 
 3. That I have carefully read and
understand this document, and either received legal advice about it before I signed it, or voluntarily declined to obtain such advice. 

 4. That the foregoing consideration is accepted voluntarily, for the purpose of making a full and final
settlement of all Claims. 
 5. That the terms of this document are intended to be contractual and not a mere recital. 
  

									
	SIGNED, SEALED, AND DELIVERED by	 	)	 		 		 	
	— on                     ,
20     in the	 	)	 		 		 	
	presence of:	 	)	 		 		 	
		 	)	 		 		 	
	  
	 	)	 		 		 	
	Signature	 	)	 		 		 	
		 	)	 		 	  
	 	
	  
	 	)	 		 	—	 	
	Print Name	 	)	 		 		 	
		 	)	 		 		 	
	  
	 	)	 		 		 	
	Address	 	)	 		 		 	
		 	)	 		 		 	
	  
	 	)	 		 		 	
	Occupation	 	)	 		 		 	

 * * PLEASE READ CAREFULLY BEFORE SIGNING * * 
  

 - 2 - 

 APPENDIX B 
 Non-Angiotech Inventions 
 Attached

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00170-of-00352.parquet"}]]